TGM2 and ovarian serous cystadenocarcinoma: Besides, according to the “Ovarian Serous Cystadenocarcinoma (TCGA)” study and using the tools from cBioportal, up-regulation of MIEN1, TGM2 or ZN428 in samples from these patients is correlated to poorer survival outcomes (Figure 4).